STX vs. ELX, APC, STK, DGI, IDEA, VLG, DNL, EAH, PXS, and CEL
Should you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), Apc Technology Group (APC), StreaksAI (STK), DG Innovate (DGI), Ideagen (IDEA), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Provexis (PXS), and Celadon Pharmaceuticals (CEL).
Shield Therapeutics vs.
El Oro (LON:ELX) and Shield Therapeutics (LON:STX) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.
El Oro has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.
Shield Therapeutics received 162 more outperform votes than El Oro when rated by MarketBeat users. Likewise, 75.17% of users gave Shield Therapeutics an outperform vote while only 59.55% of users gave El Oro an outperform vote.
11.9% of Shield Therapeutics shares are owned by institutional investors. 62.2% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Shield Therapeutics' average media sentiment score of 1.22 beat El Oro's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the news media.
El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -173.43%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.
Summary
Shield Therapeutics beats El Oro on 7 of the 11 factors compared between the two stocks.
Get Shield Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shield Therapeutics Competitors List
Related Companies and Tools
This page (LON:STX) was last updated on 2/22/2025 by MarketBeat.com Staff
